C81.27
Mixed cellularity Hodgkin lymphoma, spleen
Clinical Classification Guidelines
Medical Intelligence & Overview
Mixed cellularity Hodgkin lymphoma is a specific subtype of Hodgkin lymphoma, a type of cancer originating in the lymphatic system. This form often affects the spleen, an organ crucial for filtering blood and supporting immune functions. Recognized by its unique cellular makeup, the mixed cellularity variant is one of the more common forms of Hodgkin lymphoma, particularly in certain age groups and regions. Understanding this condition involves knowing its causes, symptoms, diagnostic methods, and treatment options.
Causes & Symptoms
Clinical Causes: Genetic factors, potentially involving inherited predispositions. Infections, notably the Epstein-Barr virus (EBV), which has been linked to Hodgkin lymphoma. Environmental exposures, including certain chemicals and radiation. Immunodeficiency states, such as HIV infection, that compromise immune function. Age-related factors, with increased incidence in young adults and older individuals.
Key Symptoms: Swelling in lymph nodes, often in the neck, armpits, or groin. Unexplained weight loss and loss of appetite. Persistent fever, typically above 101°F (38.3°C). Night sweats that may soak clothing and bedding. Fatigue and general weakness. Itching all over the body without an apparent reason. Enlargement of the spleen, which may cause discomfort or a feeling of fullness in the upper left abdomen. Pain or swelling in the lymph nodes after consuming alcohol (less common).
Diagnostic & Treatment
Diagnosis Path: Diagnosing mixed cellularity Hodgkin lymphoma involves multiple steps: - **Physical Examination:** Checking for swollen lymph nodes and signs of spleen enlargement. - **Imaging Tests:** PET scans and CT scans to visualize affected areas and determine the extent of the disease. - **Biopsy:** Removing a lymph node or spleen tissue sample for microscopic examination to identify Reed-Sternberg cells characteristic of Hodgkin lymphoma. - **Laboratory Tests:** Blood tests to assess overall health, organ function, and presence of infection or other markers. - **Additional Tests:** Bone marrow biopsy if spread beyond lymph nodes or spleen is suspected.
Treatment Protocols: Treatment strategies are tailored to the disease stage and patient health status: - **Chemotherapy:** The cornerstone of Hodgkin lymphoma treatment, often using combination regimens like ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine). - **Radiation Therapy:** Targeted radiation may be used to eliminate residual cancer cells, especially in localized disease. - **Stem Cell Transplant:** Considered in cases where the disease recurs or does not respond to initial treatments. - **Targeted Therapy:** Newer agents that specifically target cancer cell mechanisms may be employed. - **Supportive Care:** Managing side effects, infections, and nutritional support during treatment. Close monitoring during and after treatment is essential for assessing response and managing potential complications.
Clinical Advice & FAQs
Billing Guidance
Is C81.27 a billable ICD-10 code?
Yes, C81.27 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.27?
Clinical documentation must specify the nature of Mixed cellularity Hodgkin lymphoma, spleen and any associated comorbidities for accurate reporting.
Cite this Clinical Reference